Mcl-1 expression is a predictive marker of response to gemcitabine plus nab-paclitaxel for metastatic pancreatic cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Mcl-1 expression is a predictive marker of response to gemcitabine plus nab-paclitaxel for metastatic pancreatic cancer ; volume:14 ; number:1 ; day:20 ; month:9 ; year:2024 ; pages:1-9 ; date:12.2024
Scientific reports ; 14, Heft 1 (20.9.2024), 1-9, 12.2024
- Creator
-
Urabe, Makiko
Ikezawa, Kenji
Seiki, Yusuke
Watsuji, Ko
Kawamoto, Yasuharu
Hirao, Takeru
Kai, Yugo
Takada, Ryoji
Yamai, Takuo
Mukai, Kaori
Nakabori, Tasuku
Uehara, Hiroyuki
Nagata, Shigenori
Ohkawa, Kazuyoshi
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-024-73020-8
- URN
-
urn:nbn:de:101:1-2412032118400.535171430752
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:28 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Urabe, Makiko
- Ikezawa, Kenji
- Seiki, Yusuke
- Watsuji, Ko
- Kawamoto, Yasuharu
- Hirao, Takeru
- Kai, Yugo
- Takada, Ryoji
- Yamai, Takuo
- Mukai, Kaori
- Nakabori, Tasuku
- Uehara, Hiroyuki
- Nagata, Shigenori
- Ohkawa, Kazuyoshi
- SpringerLink (Online service)
Other Objects (12)
Pankreaskarzinom nab-Paclitaxel
Breast cancer nab-Paclitaxel
Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer
Nab-Paclitaxel beim NSCLC : therapeutischer Stellenwert von Nab-Paclitaxel in der Therapie des nicht kleinzelligen Lungenkarzinoms (NSCLC)
Necrosis of Pedunculated Lipofibroma by Nab-Paclitaxel
Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer
Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine
NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice
Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer
Neoadjuvant nab-paclitaxel in the treatment of breast cancer
Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer
Pankreaskarzinom nab-Paclitaxel
Breast cancer nab-Paclitaxel
Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer
Nab-Paclitaxel beim NSCLC : therapeutischer Stellenwert von Nab-Paclitaxel in der Therapie des nicht kleinzelligen Lungenkarzinoms (NSCLC)
Necrosis of Pedunculated Lipofibroma by Nab-Paclitaxel
Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer
Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine
NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice
Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer
Neoadjuvant nab-paclitaxel in the treatment of breast cancer
Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer
Pankreaskarzinom nab-Paclitaxel
Breast cancer nab-Paclitaxel
Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer
Nab-Paclitaxel beim NSCLC : therapeutischer Stellenwert von Nab-Paclitaxel in der Therapie des nicht kleinzelligen Lungenkarzinoms (NSCLC)
Necrosis of Pedunculated Lipofibroma by Nab-Paclitaxel
Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer
Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine
NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice
Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer
Neoadjuvant nab-paclitaxel in the treatment of breast cancer